Clinical trials: Cancer Patient
Carcinoma, Non-Small-Cell Lung
BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST criteria in patients with EGFR FISH positive…
- Trial name
- NCT00796549
- Testing
- BiBW 2992
- Where
- 13 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
This research is being done to test an investigational drug, called itraconazole, in the treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration (FDA) for the treatment of various fungal…
- Trial name
- NCT00887458
- Testing
- Itraconazole 200 mg, Itraconazole 300mg
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Johns Hopkins University
Lymphoma, Advanced Cancer
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
The purpose of this study was to assess the effect of tasisulam as an inhibitor of CYP2C9, using tolbutamide as a probe substrate. This study was to have 3 treatment periods, and continued access in an extension period.
- Trial name
- JZAR (NCT01185548)
- Testing
- Tolbutamide, Tasisulam
- Where
- 5 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
This phase II trial is studying how well 17-AAG works in treating patients with metastatic prostate cancer that did not respond to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00118092
- Testing
- tanespimycin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
The purpose of this study is to find out how effective this combination is as a second line treatment for colorectal cancer that has spread from one part of the body to another (metastasized) or has not metastasized but is…
- Trial name
- NCT00574171
- Testing
- lapatinib, Capecitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Wisconsin, Madison
Pancreatic Neoplasms
A Study for Participants With Pancreatic Cancer
The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study.
- Trial name
- NCT00839332
- Testing
- LY2603618, Gemcitabine
- Where
- 30 sites in United States, Germany and 4 more
- Volunteers
- 157 people
- Sponsor
- Eli Lilly and Company
Hodgkin's Lymphoma
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
The primary objective was to provide drug to ongoing patients who were receiving panobinostat and to characterize the safety and tolerability of panobinostat in patients with HL after achieving a complete response following…
- Trial name
- PATH (NCT01034163)
- Testing
- Panobinostat
- Where
- 35 sites in United States, Australia and 12 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect.
- Trial name
- NCT01181258
- Testing
- Rituximab, Interleukin-2, Natural killer cells
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase II trial studies the side effects and how well giving combination chemotherapy together with dasatinib works in treating patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Trial name
- NCT01238211
- Testing
- Cytarabine, Dasatinib, Daunorubicin Hydrochloride
- Where
- 65 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
HER2 Positive Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
This phase II trial studies the side effects of and how well neratinib works in treating older patients with stage IV HER2-positive breast cancer.
- Trial name
- NCT02673398
- Testing
- Comprehensive Geriatric Assessment, Laboratory Biomarker Analysis, Neratinib
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone…
- Trial name
- NCT00877006
- Testing
- bendamustine, rituximab, vincristine
- Where
- 128 sites in United States, Australia and 5 more
- Volunteers
- 447 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Colorectal Cancer, Neurotoxicity
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
RATIONALE: Calcium gluconate and magnesium sulfate may prevent or lessen neurotoxicity caused by oxaliplatin. It is not yet known whether calcium gluconate and magnesium sulfate are more effective than a placebo in preventing…
- Trial name
- NCT00316914
- Testing
- calcium gluconate, magnesium sulfate
- Where
- 14 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage IV NSCLC
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
This pilot phase I trial aims to investigate the safety and tolerability of anti-programmed cell death-1 (PD-1) monoclonal antibody Sintilimab (also called IBI308) in combination with concurrent stereotactic body radiation…
- Trial name
- NCT03812549
- Testing
- Sintilimab, stereotactic body radiation therapy, Low Dose Radiotherapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sichuan University
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03448458
- Testing
- CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Emory University
Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).
- Trial name
- NCT02783599
- Testing
- Olaratumab, Doxorubicin, External Beam Radiotherapy
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 51 people
- Sponsor
- Eli Lilly and Company
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Central Nervous System Lymphoma, Malignant Glioma
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer…
- Conditions
- Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT00103038
- Testing
- 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- OHSU Knight Cancer Institute
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph…
- Conditions
- Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive, Invasive Breast Carcinoma, Progesterone Receptor Positive
- Trial name
- TRIUMPH-T (NCT02526498)
- Testing
- Accelerated Partial Breast Irradiation, High-Dose Rate Brachytherapy, Questionnaire Administration
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Rutgers, The State University of New Jersey
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.